NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

VYNE

VYNE Therapeutics Inc

Jul 09 • 04:00PM ET

1.44

Dollar change +0.06
Percentage change 4.35	%

Healthcare • Biotechnology • USA • NASD

Peers: AVTX ARDX ACEL MCRB ANAB XFOR CLGN HYPD MRNS VTVT

| Held by: VTI VXF

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.99	Insider Own	18.19%	Shs Outstand	15.96M	Perf Week	-18.64%
Market Cap	24.00M	Forward P/E	-	EPS next Y	-0.74	Insider Trans	0.50%	Shs Float	13.63M	Perf Month	44.00%
Enterprise Value	-26.21M	PEG	-	EPS next Q	-0.22	Inst Own	36.72%	Short Float	2.53%	Perf Quarter	-6.49%
Income	-42.19M	P/S	40.00	EPS this Y	-10.14%	Inst Trans	1.63%	Short Ratio	0.57	Perf Half Y	-58.38%
Sales	0.60M	P/B	0.52	EPS next Y	28.14%	ROA	-56.95%	Short Interest	0.34M	Perf YTD	-57.01%
Book/sh	2.77	P/C	0.48	EPS next 5Y	11.71%	ROE	-66.15%	52W High	4.30 -66.51%	Perf Year	-21.74%
Cash/sh	3.02	P/FCF	-	EPS past 3/5Y	66.84% 65.87%	ROIC	-95.59%	52W Low	0.85 69.41%	Perf 3Y	-81.69%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-18.66% 2.49%	Gross Margin	-	Volatility	14.42% 14.29%	Perf 5Y	-98.84%
Dividend TTM	-	EV/Sales	-43.68	EPS Y/Y TTM	81.75%	Oper. Margin	-7513.06%	ATR (14)	0.18	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	4.47	Sales Y/Y TTM	43.03%	Profit Margin	-6972.73%	RSI (14)	56.49	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	4.47	EPS Q/Q	-37.65%	SMA20	19.11%	Beta	1.83	Target Price	6.38
Payout	-	Debt/Eq	0.00	Sales Q/Q	106.12%	SMA50	21.45%	Rel Volume	0.66	Prev Close	1.38
Employees	13	LT Debt/Eq	0.00	Earnings	May 08 BMO	SMA200	-31.36%	Avg Volume	601.69K	Price	1.44
IPO	Jan 25, 2018	Option/Short	No / Yes	EPS/Sales Surpr.	30.65% 304.00%	Trades		Volume	395,089	Change	4.35%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-18-24	Initiated	BTIG Research	Buy	$8
Dec-06-21	Resumed	H.C. Wainwright	Buy	$7

Jul-02-25 07:45AM	VYNE Therapeutics Provides Program Update on Oral BET inhibitor VYN202 (GlobeNewswire) -14.69%
May-08-25 08:00AM	VYNE Therapeutics Reports 2025 First Quarter Financial Results and Provides Business Update (GlobeNewswire) -5.11%
Apr-25-25 08:00AM	VYNE Therapeutics Provides Update on VYN202 Program (GlobeNewswire) -23.94%
Mar-20-25 08:00AM	VYNE Therapeutics to Participate in the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference (GlobeNewswire) -5.08%
Mar-06-25 08:00AM	VYNE Therapeutics Reports 2024 Fourth Quarter and Year-End Financial Results and Provides Business Update (GlobeNewswire)
08:00AM	Loading…
Feb-20-25 08:00AM	VYNE Therapeutics to Participate in March Investor Conferences (GlobeNewswire) +7.14%
Feb-19-25 08:00AM	VYNE Therapeutics Initiates Phase 1b Trial of VYN202, a Novel BD2-Selective Oral BET Inhibitor, in Plaque Psoriasis (GlobeNewswire)
Jan-06-25 07:30AM	VYNE Therapeutics Completes Enrollment in Phase 2b Trial Evaluating VYN201 for the Treatment of Nonsegmental Vitiligo (GlobeNewswire) +15.61%
Dec-24-24 09:51AM	H.C. Wainwright says VYNEs VYN202 becomes pick of the crop after MAD data (TipRanks) +15.56%
Dec-23-24 07:30AM	VYNE Therapeutics Reports Positive Top-line Phase 1a MAD Data for VYN202, its Novel BD2-Selective BET Inhibitor (GlobeNewswire)
Nov-19-24 06:15AM	VYNE Therapeutics initiated with a Buy at BTIG on I&I potential (TipRanks)
Nov-07-24 08:00AM	VYNE Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Sep-12-24 08:00AM	VYNE Therapeutics Announces Positive Phase 1a SAD Data for VYN202, a Novel BD2-Selective BET Inhibitor (GlobeNewswire)
Sep-03-24 08:00AM	VYNE Therapeutics to Participate in September Investor Conferences (GlobeNewswire)
Aug-14-24 08:00AM	VYNE Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
08:00AM	Loading…
Jul-16-24 08:00AM	VYNE Therapeutics Announces Granting of Composition of Matter Patent for VYN202, a Novel BD2-Selective BET Inhibitor (GlobeNewswire)
Jul-09-24 08:00AM	VYNE Therapeutics Announces Appointment of Subhashis Banerjee, M.D. as Senior Vice President of Clinical Development (GlobeNewswire)
Jun-26-24 08:00AM	VYNE Therapeutics to Participate in Leerink Partners Therapeutics Forum (GlobeNewswire) -7.51%
Jun-13-24 09:02AM	VYNE Therapeutics Announces Dosing of First Participants in Phase 1a Trial of Novel BD2-Selective BET Inhibitor VYN202 (GlobeNewswire)
Jun-05-24 08:00AM	VYNE Therapeutics Announces Dosing of First Subject in Phase 2b Vitiligo Trial of Novel BET Inhibitor VYN201 (GlobeNewswire)
May-09-24 01:54PM	VYNE Stock Earnings: VYNE Therapeutics Beats EPS, Misses Revenue for Q1 2024 (InvestorPlace)
09:15AM	VYNE Therapeutics Inc. (VYNE) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
08:00AM	VYNE Reports First Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
May-06-24 08:00AM	VYNE Therapeutics Announces FDA Clearance of IND Application for VYN202, a Novel BD2-Selective BET Inhibitor (GlobeNewswire)
May-01-24 08:00AM	VYNE Therapeutics Announces Oral Presentations for VYN201 at the 2024 Society for Investigative Dermatology (SID) Annual Meeting (GlobeNewswire)
Mar-19-24 08:00AM	VYNE Therapeutics to Participate in the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference (GlobeNewswire) +8.85%
Mar-13-24 09:55AM	Here's Why VYNE Therapeutics Inc. (VYNE) Is a Great 'Buy the Bottom' Stock Now (Zacks)
Mar-08-24 12:00PM	What Makes VYNE Therapeutics Inc. (VYNE) a New Buy Stock (Zacks)
Feb-29-24 08:00AM	VYNE Reports 2023 Fourth Quarter and Year-End Financial Results and Provides Business Update (GlobeNewswire)
Feb-27-24 08:00AM	VYNE Therapeutics to Present Results of the Phase 1b Trial for VYN201 at the 2024 Global Vitiligo Foundation Annual Scientific Symposium (GlobeNewswire)
08:00AM	Loading…
Feb-21-24 08:00AM	VYNE Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference (GlobeNewswire)
Jan-10-24 08:00AM	VYNE Therapeutics Announces Positive Biomarker Data from Successful Phase 1b Trial of VYN201 for the Treatment of Vitiligo (GlobeNewswire)
Jan-03-24 08:00AM	VYNE Therapeutics Appoints Christine Borowski, Ph.D., to its Board of Directors (GlobeNewswire)
Nov-13-23 07:45AM	VYNE Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
Nov-07-23 08:00AM	VYNE Therapeutics to Host Virtual R&D Day Event on November 9, 2023 (GlobeNewswire) +7.67%
Nov-01-23 04:15PM	VYNE Therapeutics Announces Closing of Previously Announced Private Placement of $88.2 Million (GlobeNewswire)
Oct-30-23 07:20AM	VYNE Therapeutics Reports Positive Results from Preclinical Models for Oral BD2-Selective BET Inhibitor VYN202 (GlobeNewswire) +23.39%
07:05AM	VYNE Therapeutics Announces Private Placement of $88 Million (GlobeNewswire)
07:00AM	VYNE Therapeutics Announces Positive Data from Phase 1b Trial for Novel BET Inhibitor VYN201 in Patients with Nonsegmental Vitiligo (GlobeNewswire)
Sep-06-23 08:00AM	VYNE Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference (GlobeNewswire)
Aug-14-23 08:00AM	VYNE Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire) +9.27%
May-18-23 08:00AM	VYNE Therapeutics to Attend BIO International Convention (GlobeNewswire) -5.57%
May-11-23 04:01PM	VYNE Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire) +18.52%
May-01-23 08:00AM	VYNE Therapeutics Announces Selection of Development Candidate VYN202, a Potential Best-in-Class Oral Small Molecule BD2-Selective BET Inhibitor for the Treatment of Immuno-Inflammatory Conditions (GlobeNewswire) +14.83%
Apr-19-23 08:00AM	VYNE Therapeutics Announces Positive Preclinical Data for Inhaled Formulation of VYN201 in an In Vivo Model of Idiopathic Pulmonary Fibrosis (GlobeNewswire) +42.49%
Mar-30-23 07:45AM	VYNE Therapeutics Announces Positive First-In-Human Pharmacokinetic and Hematology Data from Phase 1a Single and Multiple Ascending Dose Trial for Novel Pan-Bromodomain BET Inhibitor VYN201 (GlobeNewswire) +16.38%
Mar-22-23 08:00AM	VYNE Therapeutics to Participate in the H.C. Wainwright Autoimmune & Inflammation Disease Virtual Conference (GlobeNewswire) -6.64%
Mar-09-23 04:01PM	VYNE Therapeutics Reports Year-End 2022 Financial Results and Provides Business Update (GlobeNewswire) -13.00%
Feb-28-23 04:00PM	VYNE Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Rule (GlobeNewswire) -10.64%
Feb-22-23 08:00AM	VYNE Therapeutics to Participate in the 43rd Annual Cowen Health Care Conference (GlobeNewswire)
Feb-15-23 08:00AM	VYNE Therapeutics Announces Positive Results from Phase 1a Single and Multiple Ascending Dose Trial for Investigational Novel BET Inhibitor VYN201 (GlobeNewswire)
Feb-10-23 08:00AM	VYNE Therapeutics Announces Reverse Stock Split (GlobeNewswire) -10.60%
Jan-09-23 04:01PM	VYNE Therapeutics Announces First Vitiligo Patient Dosed in Phase 1a/b Clinical Trial of Novel BET Inhibitor VYN201 (GlobeNewswire) -15.04% +45.83%
Dec-12-22 08:00AM	VYNE Therapeutics to Participate in the LifeSci Partners 12th Annual Corporate Access Event (GlobeNewswire) -14.94%
Dec-07-22 08:00AM	VYNE Therapeutics Announces First Patent Granted for Novel BET Inhibitor Platform (GlobeNewswire)
Dec-02-22 08:00AM	VYNE Therapeutics to Participate in Cantor Fitzgeralds Medical & Aesthetic Dermatology, Ophthalmology & MedTech Conference (GlobeNewswire)
Nov-18-22 08:00AM	VYNE Therapeutics to Present at Piper Sandler 34th Annual Healthcare Conference (GlobeNewswire)
Nov-17-22 08:00AM	VYNE Therapeutics Announces First Subjects Dosed in Phase 1a/b Clinical Trial Evaluating Pan-BET Inhibitor, VYN201, for the Treatment of Vitiligo (GlobeNewswire)
Nov-10-22 04:01PM	VYNE Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update (GlobeNewswire) +7.96%
Sep-06-22 08:00AM	VYNE Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference (GlobeNewswire)
Aug-12-22 08:00AM	VYNE Therapeutics Reports Second Quarter 2022 Financial Results (GlobeNewswire)
Aug-10-22 08:32AM	VYNE Therapeutics Announces Results from its Phase 2a Trial of FMX114 for the Treatment of Mild-to-Moderate Atopic Dermatitis (GlobeNewswire) -22.92%
Jul-19-22 08:00AM	VYNE Therapeutics to Present at the B&T Cell-Mediated Autoimmune Disease Drug Development Conference (GlobeNewswire)
Jun-17-22 08:00AM	VYNE Therapeutics Completes Enrollment in Phase 2a Trial of FMX114 for the Treatment of Mild-to-Moderate Atopic Dermatitis (GlobeNewswire)
May-18-22 08:00AM	VYNE Therapeutics to Present at HC Wainwright & Co. Global Investment Conference (GlobeNewswire)
May-12-22 04:05PM	VYNE Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Update (GlobeNewswire) +7.25%
May-10-22 08:00AM	VYNE Hosting Key Opinion Leader Event on Novel InhiBET BET Inhibitor Platform (GlobeNewswire)
May-06-22 08:00AM	VYNE Therapeutics to Present at LifeSci Partners Immunology & Inflammation Symposium on May 10th (GlobeNewswire)
May-05-22 02:06PM	Companies Like VYNE Therapeutics (NASDAQ:VYNE) Could Be Quite Risky (Simply Wall St.) -5.48%
Apr-28-22 03:02PM	VYNE Therapeutics Inc. (VYNE) May Report Negative Earnings: Know the Trend Ahead of Q1 Release (Zacks) -5.15%
Apr-07-22 08:00AM	VYNE Therapeutics Announces Positive Phase 1b Efficacy Data for FMX114 from Phase 1b/2a Trial for the Treatment of Mild-to-Moderate Atopic Dermatitis (GlobeNewswire) +9.51%
Mar-30-22 08:00AM	VYNE Reports Positive Preclinical Data for Intra-Articular Injection of Pan-BET Inhibitor, VYN201, in an In Vivo Model of Rheumatoid Arthritis (GlobeNewswire) +7.02%
Mar-17-22 08:00AM	VYNE Therapeutics Reports Year-End 2021 Financial Results and Provides Corporate Update (GlobeNewswire) +6.09%
Mar-07-22 07:00AM	VYNE Reports Positive Preclinical Data for Lead BET Inhibitor, VYN201, in Human Skin Model of Vitiligo (GlobeNewswire)
Mar-03-22 08:00AM	VYNE Therapeutics to Present at 42nd Annual Cowen Healthcare Conference (GlobeNewswire) -5.32%
Jan-19-22 08:00AM	VYNE Therapeutics Announces Phase 1b Data for FMX114 from Phase 1b/2a Trial for the Treatment of Mild-to-Moderate Atopic Dermatitis (GlobeNewswire)
Jan-13-22 07:00AM	VYNE Therapeutics Divests Topical Minocycline Assets (GlobeNewswire) -21.45%
Jan-03-22 08:00AM	VYNE Therapeutics to Participate at the LifeSci Partners 11th Annual Corporate Access Event (GlobeNewswire) +10.78%
Dec-13-21 12:08PM	Do Options Traders Know Something About VYNE Therapeutics (VYNE) Stock We Don't? (Zacks) -18.67%
Nov-18-21 08:00AM	VYNE Therapeutics to Present at the Piper Sandler 33rd Annual Virtual Healthcare Conference (GlobeNewswire) -5.13%
Nov-12-21 01:09PM	VYNE Therapeutics (NASDAQ:VYNE) investors are sitting on a loss of 80% if they invested a year ago (Simply Wall St.)
Nov-10-21 07:30AM	VYNE Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Update (GlobeNewswire)
Nov-04-21 08:00AM	Lead BET Inhibitor, VYN201, Demonstrates Improvement in Reducing Fibrotic Tissue Mass and Overall Skin Repair Outcomes in Preclinical Study (GlobeNewswire)
Oct-28-21 03:05PM	VYNE Therapeutics Inc. (VYNE) May Report Negative Earnings: Know the Trend Ahead of Q3 Release (Zacks)
08:00AM	VYNE Therapeutics to Report Third Quarter 2021 Financial Results on November 10, 2021 (GlobeNewswire)
Oct-26-21 08:00AM	Lead BET Inhibitor, VYN201, Significantly Reduces Expression of Several Key Pro-Inflammatory Cytokines in Preclinical Studies (GlobeNewswire) +14.41%
Oct-21-21 08:00AM	VYNE Therapeutics Announces Formation of Scientific Advisory Board (GlobeNewswire)
Oct-19-21 08:00AM	VYNE Therapeutics Enrolls First Patient in Clinical Trial of FMX114 for the Treatment of Mild-to-Moderate Atopic Dermatitis (GlobeNewswire)
Oct-05-21 08:00AM	VYNE Therapeutics Announces its China Partners Enrollment of First Patient in Phase 3 Study of AMZEEQ® in Patients with Moderate to Severe Acne (GlobeNewswire) -5.56%
Sep-20-21 08:00AM	VYNE Therapeutics to Present at the Cantor Fitzgerald Investment Conference (GlobeNewswire) -5.73%
Sep-08-21 08:00AM	VYNE Therapeutics to Present at the H.C. Wainwright Annual Investment Conference (GlobeNewswire)
Aug-13-21 07:11AM	Revenue Downgrade: Here's What Analysts Forecast For VYNE Therapeutics Inc. (NASDAQ:VYNE) (Simply Wall St.) -10.55%
Aug-12-21 07:30AM	VYNE Therapeutics Reports Second Quarter 2021 Financial Results and Announces New Strategic Direction to Develop Treatments for Immunological and Inflammatory Diseases (GlobeNewswire) -31.14%
07:00AM	VYNE Therapeutics Announces Licensing of BET Inhibitor Platform for Immuno-Inflammatory Conditions with In4Derm Limited (GlobeNewswire)
Aug-11-21 08:43AM	Are Institutions Heavily Invested In VYNE Therapeutics Inc.'s (NASDAQ:VYNE) Shares? (Simply Wall St.) +5.47%
Aug-05-21 03:01PM	VYNE Therapeutics Inc. (VYNE) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release (Zacks)
Aug-02-21 08:00AM	VYNE Therapeutics Announces Approval of AMZEEQ® (Minocycline) and ZILXI® (Minocycline) in Chinese Economic Pilot Zone (GlobeNewswire)
Jul-27-21 08:00AM	VYNE Therapeutics to Report Second Quarter 2021 Financial Results on August 12, 2021 (GlobeNewswire)
Jul-19-21 08:00AM	VYNE Therapeutics Announces Initiation of Investigator Initiated Trial Evaluating AMZEEQ® (Minocycline) with Oral Isotretinoin in Patients with Moderate to Severe Acne (GlobeNewswire)
Jun-29-21 08:00AM	VYNE Therapeutics to Participate in the 2nd Annual JAK Inhibitors Drug Development Digital Event (GlobeNewswire)

VYNE Therapeutics, Inc. engages in the manufacture of pharmaceutical products. It develops and commercializes solutions using its proprietary Molecule Stabilizing Technology. Its commercial products include AMZEEQ and ZILXI. The company was founded in October 2011 and is headquartered in Bridgewater, NJ.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
LEPORE PATRICK G	Director	Jan 15 '25	Buy	2.92	15,000	43,800	51,472	Jan 16 06:06 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

VYNE

VYNE Therapeutics Inc

Upgrade your FINVIZ experience